JPWO2019224718A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019224718A5
JPWO2019224718A5 JP2020565292A JP2020565292A JPWO2019224718A5 JP WO2019224718 A5 JPWO2019224718 A5 JP WO2019224718A5 JP 2020565292 A JP2020565292 A JP 2020565292A JP 2020565292 A JP2020565292 A JP 2020565292A JP WO2019224718 A5 JPWO2019224718 A5 JP WO2019224718A5
Authority
JP
Japan
Prior art keywords
seq
nos
lcdr3
lcdr1
lcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524250A (ja
JP2021524250A5 (https=
JP7361727B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054189 external-priority patent/WO2019224718A2/en
Publication of JP2021524250A publication Critical patent/JP2021524250A/ja
Publication of JPWO2019224718A5 publication Critical patent/JPWO2019224718A5/ja
Publication of JP2021524250A5 publication Critical patent/JP2021524250A5/ja
Application granted granted Critical
Publication of JP7361727B2 publication Critical patent/JP7361727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565292A 2018-05-24 2019-05-21 Psma結合剤及びその使用 Active JP7361727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676099P 2018-05-24 2018-05-24
US62/676,099 2018-05-24
PCT/IB2019/054189 WO2019224718A2 (en) 2018-05-24 2019-05-21 Psma binding agents and uses thereof

Publications (4)

Publication Number Publication Date
JP2021524250A JP2021524250A (ja) 2021-09-13
JPWO2019224718A5 true JPWO2019224718A5 (https=) 2022-06-20
JP2021524250A5 JP2021524250A5 (https=) 2022-06-20
JP7361727B2 JP7361727B2 (ja) 2023-10-16

Family

ID=67253934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565292A Active JP7361727B2 (ja) 2018-05-24 2019-05-21 Psma結合剤及びその使用

Country Status (25)

Country Link
US (1) US11746157B2 (https=)
EP (1) EP3802609A2 (https=)
JP (1) JP7361727B2 (https=)
KR (1) KR20210015902A (https=)
CN (1) CN112513085B (https=)
AR (1) AR116173A1 (https=)
AU (1) AU2019274657A1 (https=)
BR (1) BR112020023872A2 (https=)
CA (1) CA3101272A1 (https=)
CL (1) CL2020003031A1 (https=)
CR (1) CR20200563A (https=)
DO (1) DOP2020000216A (https=)
EA (1) EA202092839A1 (https=)
EC (1) ECSP20082991A (https=)
IL (1) IL278888A (https=)
JO (1) JOP20200303A1 (https=)
MA (1) MA52777A (https=)
MX (1) MX2020012598A (https=)
NI (1) NI202000086A (https=)
PE (1) PE20211916A1 (https=)
PH (1) PH12020551997A1 (https=)
SG (1) SG11202011633SA (https=)
TW (1) TW202016135A (https=)
UY (1) UY38244A (https=)
WO (1) WO2019224718A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗pd−1配列を用いた二重特異性および単一特異性抗体
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
BR112021020532A2 (pt) * 2019-04-19 2022-03-15 Janssen Biotech Inc Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
EP3956023A1 (en) * 2019-04-19 2022-02-23 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- psma/cd3 antibody
CR20210556A (es) 2019-05-10 2021-12-17 Janssen Biotech Inc Quelantes macrocíclicos y métodos de uso de estos
WO2021231976A1 (en) * 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3183689A1 (en) 2020-05-20 2021-11-25 Janssen Biotech, Inc. Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
WO2021234593A1 (en) 2020-05-20 2021-11-25 Janssen Biotech, Inc. Methods for site specific conjugation of proteins containing glycosylated fc domains
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
CN116472060A (zh) * 2020-09-02 2023-07-21 健玛保 抗体疗法
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
IL302759A (en) 2020-11-10 2023-07-01 Janssen Biotech Inc Macrocyclic compounds and methods of use thereof
FI4284512T3 (fi) * 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
US20240059789A1 (en) * 2021-01-28 2024-02-22 Janssen Biotech, Inc. Psma binding proteins and uses thereof
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Cd3及びcldn6に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Cd3及びgpc3に結合するヘテロ二量体抗体
JP2024517701A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 組換え生産タンパク質の低分子量種を低減させる方法
US12600764B2 (en) * 2021-08-27 2026-04-14 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (COV) variants
US20250145646A1 (en) 2021-11-09 2025-05-08 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
WO2023084396A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
US20260001962A1 (en) 2022-03-21 2026-01-01 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
TW202405015A (zh) * 2022-04-11 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合psma和cd28的抗原結合分子及其醫藥用途
EP4637835A1 (en) * 2022-12-22 2025-10-29 Janssen Pharmaceutica NV Methods of preparing antibody-polynucleotide conjugates
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
WO2025096433A1 (en) * 2023-10-30 2025-05-08 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗vegf抗体
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ATE344801T1 (de) 1999-12-29 2006-11-15 Immunogen Inc Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
DK1687066T3 (da) 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
AU2005252110B2 (en) 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007004415A1 (ja) 2005-07-01 2007-01-11 Murata Manufacturing Co., Ltd. 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
ES2376771T3 (es) 2006-08-21 2012-03-16 Genentech, Inc. Compuestos aza-benzofuranilo y métodos de utilización
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
AU2008343065B2 (en) 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン, エルエルシー キナーゼインヒビターおよび使用方法
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
JP6126782B2 (ja) 2008-10-01 2017-05-10 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 異種間特異的psma×cd3二重特異性単鎖抗体
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック, インコーポレイテッド Pd−1軸結合アンタゴニストとmek阻害剤を使用する癌の治療方法
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2855531A1 (en) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
CN113201073A (zh) 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
UA129760C2 (uk) 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
JO3568B1 (ar) 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
EP3292222B1 (en) * 2015-05-06 2025-09-03 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type iii domains
US10844122B2 (en) * 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP3411404B1 (en) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma and cd3 bispecific t cell engaging antibody constructs
WO2018042071A1 (en) 2016-08-30 2018-03-08 Nokia Technologies Oy Controlling transmission of information on radio links used in aggregation
EP3727474A1 (en) * 2017-12-18 2020-10-28 Janssen Biotech, Inc. Radiolabeling of polypeptides
US12012461B2 (en) * 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2019224718A5 (https=)
ES2801873T3 (es) Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos
US12528876B2 (en) CD73 blocking antibodies
TWI851585B (zh) 抗steap1抗原結合蛋白
US11639388B2 (en) CD3 antigen binding fragment and application thereof
CA2999284C (en) Binding molecules with modified j-chain
US20250136720A1 (en) Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer
CN115894701A (zh) 结合cd3的抗体及其用途
TW200918556A (en) Treatment of tumors using specific anti-L1 antibody
CN118317975A (zh) 靶向baff-r的抗体及其用途
JP2021524255A5 (https=)
EP4289866A2 (en) Anti-pd-1 antibody and use thereof
TWI883571B (zh) 標靶cd3的抗體及其用途
JP7510209B2 (ja) ヘルパーT細胞TGF-βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
JPWO2019224713A5 (https=)
TWI866210B (zh) 雙功能蛋白質及其製劑和用途
TW202440645A (zh) 抗muc17*cd3*cd28三特異性抗體
JP2026505164A (ja) 抗cmet抗体及びその使用方法
WO2026057723A1 (en) Claudin-1/egfr bispecific antibodies for targeted degradation
WO2026057702A1 (en) Claudin-1/egfr bispecific antibodies
WO2025044937A1 (zh) 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用
CN120554510A (zh) 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物
TW202434635A (zh) 多特異性抗體及其醫藥用途
CN118894944A (zh) 抗密蛋白双特异性抗体